Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SOU-003 is a topical formulation of ebselen, a small molecule glutathione peroxidase (GPx) mimic, developed by Sound Pharmaceuticals for the treatment of noise-induced hearing loss and tinnitus. Ebselen is a synthetic organoselenium compound that mimics the activity of the antioxidant enzyme glutathione peroxidase, which plays a critical role in protecting cells from oxidative damage by reducing reactive oxygen species (ROS). In the inner ear, oxidative stress is a primary driver of hair cell death and subsequent hearing loss following exposure to loud noise or ototoxic drugs. By mimicking GPx activity, SOU-003 aims to neutralize ROS and mitigate inflammatory responses in the cochlea. While Sound Pharmaceuticals has primarily focused on the clinical development of the oral formulation (SPI-1005), SOU-003 was designed for localized otic delivery to provide targeted protection of the auditory system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SOU-003.